Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

Observational study of up to 229 people with newly diagnosed stage II-III invasive HER2-positive or triple-negative breast cancer planned for neoadjuvant therapy. The registry primary outcome is correlation of absent plasma tumor DNA with pathologic complete response. ClinicalTrials.gov lists the study as completed and does not assign a phase. Meeting reports refer to this record as PREDICT-DNA (TBCRC 040).

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins